Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New spinout enterprise from Oxford seeks to accelerate evidence based innovation for treatments and services in mental health and dementia.

Cristal Health (established in May 2019) has been developed as a sustainable way to accelerate the UK-CRIS programme. The UK-CRIS network operates a managed service for secure access to one of the world's largest repositories of de-identified patient data relating to mental health and dementia conditions.

 

Cristal Health presents a real opportunity for accelerating and translating new discovery medicine, including prevention and treatment, into better health outcomes for sufferers of mental illness and their families. - Mike Dennis, CEO, Cristal Health

Mike Denis, CEO, Cristal Health, said,

"I'm honoured to be leading the team in the joint partnership between the NHS and academia working with industry using real world health data. We're able to add value by continually enriching the clinical content available to clinicians, researchers and scientists which will truly deliver many more opportunities to predict, identify, prevent or manage mental health conditions in the UK." 

The market for real world evidence and data is projected to grow as organisations seek to reduce costs and time, 

 

The spinning out of remarkable new companies like Cristal Health is great news. It brings in investment which allows for exciting initiatives and innovative activity developed in the NHS and Universities to grow more quickly and become sustainable. Everyone benefits and most importantly our patients. - Professor John Geddes, Head of Department of Psychiatry

Cristal Health will focus on three areas:

• Developing offerings to help in early stage drug discovery, reduce clinical trial costs by 12-30%, support post launch and Phase IV evaluation (i.e. following approval) and pharmacovigilance (safety monitoring).

• Supporting NHS Trusts in generating revenue from increased participation in the global trials market and developing tools that support service reviews through ongoing monitoring

• Supporting academic research by developing tools to support text-mining to create real knowledge from distributed and heterogeneous data

Cristal Health will use any profits generated to re-invest into its core purpose of accelerating improvements in medical research, services and outcomes for patients with a mental illness and/or dementia.

To find out more about Cristal Health contact: CEO, Mike Denis, Mike@cristalhealth.co.uk or CIO David, Newton, David@cristalhealth.co.uk.

 

 

Similar stories

New Analysis Challenges Guidelines on Treating Anorexia Nervosa

Research Highlights

A new analysis, published in The Lancet Psychiatry, has shown a lack of strong evidence to support current guidance on psychological therapies for treating anorexia nervosa over expert treatment as usual.

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Research Highlights

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

How the brain reorganises old memories when new ones are made

Research Highlights

Researchers have discovered that the arrangement of existing memories in the brain is altered when we embed new memories

New WA Handley Chair of Psychiatry Appointed

Strategic Developments

Professor John Geddes has been appointed to the WA Handley Professorship of Psychiatry and will take up this post in November 2021.

Improving Experiences of People with Serious Mental Health Problems

Research Highlights

A project led by Professor Kam Bhui and Dr Roisin Mooney, University of Oxford, will focus on reducing the number of people admitted or readmitted to compulsory care under the Mental Health Act. This is one of four new research projects funded by the National Institute for Health Research (NIHR) with the aim to improve patient experiences and outcomes under the Mental Health Act.

Potential New Target to Prevent or Delay Dementia

Research Highlights

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.